Lorigerlimab

Phase 2Monoclonal antibody

MMacroGenics

Lorigerlimab is one of 166 biologic programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic AdenocarcinomaNot yet recruiting

Colorectal CancerRecruiting

Prostate CancerActive, not recruiting

Advanced Solid TumorsRecruiting

Metastatic CancerRecruiting

Pancreatic AdenocarcinomaPhase 2

Not yet recruiting

Colorectal CancerPhase 2

Recruiting

Prostate CancerPhase 2

Active, not recruiting

Advanced Solid TumorsPhase 2

Recruiting

Metastatic CancerPhase 2

Recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

21 2

Keytruda

Merck & Co.

Phase 3

21 3

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 4

Glucophage

EMD Serono

Phase 3

14 5

Lorigerlimab

MMacroGenics

Phase 2

1 6

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 7

Trexall

Jazz Pharmaceuticals

Preclinical

—8

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Advanced Solid Tumors

NCT06730347

Q2 2028

Phase 2Recruiting

Metastatic Cancer

NCT05475171

Q2 2029

Phase 2Recruiting

Colorectal Cancer

NCT07071961

Q1 2032

Phase 2Not yet recruiting

Pancreatic Adenocarcinoma

NCT07565155

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Recruiting·MMacroGenics·Phase 2·NCT06730347·60 enrolled

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Completed·MMacroGenics·Phase 1·NCT05293496·31 enrolled

Metastatic Cancer2 trials

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Completed·MMacroGenics·Phase 1·NCT03761017·162 enrolled

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05475171·60 enrolled

Metastatic Colorectal Cancer1 trial

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT07137390

Prostate Cancer1 trial

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·MMacroGenics·Phase 2·NCT05848011·154 enrolled

Rectal Cancer1 trial

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT07223567

2 more indications

Pancreatic Adenocarcinoma1 trial

A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Not yet recruiting·UUniversity of Miami·Phase 2·NCT07565155·40 enrolled

Colorectal Cancer1 trial

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07071961·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Lorigerlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lorigerlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lorigerlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MacroGenics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMacroGenics

Lorigerlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q2 2029

Q1 2032

Trials by Indication[1]

Advanced Solid Tumors2 trials

Metastatic Cancer2 trials

Metastatic Colorectal Cancer1 trial

Prostate Cancer1 trial

Rectal Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News